Literature DB >> 9703877

Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver.

S Kuriyama1, K Tominaga, M Kikukawa, T Nakatani, H Tsujinoue, M Yamazaki, S Nagao, Y Toyokawa, A Mitoro, H Fukui.   

Abstract

Recent advances in molecular biology have made gene therapy for cancer feasible in clinical trials. Although recombinant adenovirus is an attractive vehicle for transferring therapeutic genes in vivo, animal studies have indicated that the clinical usefulness of adenovirus vectors may be limited by their immunogenicity. It has been shown that neutralizing antibodies against adenoviruses reduce the efficiency of vector readministration. It is of great importance to examine the effects of human sera on adenovirus-mediated gene transfer, because the majority of prospective gene therapy patients are likely to have been exposed to wild-type adenoviruses. In the present study, it was shown that anti-adenovirus antibody-positive human sera with the lowest positive titer substantially inhibit the adenovirus-mediated gene transfer not only in vitro but also in vivo. These results may have important implications for efficacy considerations when adenovirus vectors are employed in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703877

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  16 in total

1.  Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors.

Authors:  Mieke C Sprangers; Wandena Lakhai; Wouter Koudstaal; Marielle Verhoeven; Björn F Koel; Ronald Vogels; Jaap Goudsmit; Menzo J E Havenga; Stefan Kostense
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

2.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

3.  Deep RNA sequencing reveals complex transcriptional landscape of a bat adenovirus.

Authors:  Lijun Wu; Peng Zhou; Xingyi Ge; Lin-Fa Wang; Michelle L Baker; Zhengli Shi
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

4.  Vaccine immunotherapy for prostate cancer: from mice to men.

Authors:  David M Lubaroff; Daniel Vaena; James A Brown; Pamela Zehr; Karen C Griffith; Erica Brown; Julie Eastman; Kenneth Nepple; Ambika Kattula; Richard D Williams
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

5.  Assessment of efficiency and safety of adenovirus mediated gene transfer into normal and damaged murine livers.

Authors:  T Nakatani; S Kuriyama; K Tominaga; T Tsujimoto; A Mitoro; M Yamazaki; H Tsujinoue; H Yoshiji; S Nagao; H Fukui
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

6.  Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.

Authors:  Qianqian Li; Qiang Liu; Weijing Huang; Aijing Song; Chenyan Zhao; Jiajing Wu; Youchun Wang
Journal:  Hum Vaccin Immunother       Date:  2017-03-16       Impact factor: 3.452

7.  Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier.

Authors:  Z Q Xiang; G P Gao; A Reyes-Sandoval; Y Li; J M Wilson; H C J Ertl
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Repeated adenoviral administration into the biliary tract can induce repeated expression of the original gene construct in rat livers without immunosuppressive strategies.

Authors:  K Tominaga; S Kuriyama; H Yoshiji; A Deguchi; Y Kita; F Funakoshi; T Masaki; K Kurokohchi; N Uchida; T Tsujimoto; H Fukui
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 9.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

10.  Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer.

Authors:  Alan L Parker; Simon N Waddington; Suzanne M K Buckley; Jerome Custers; Menzo J E Havenga; Nico van Rooijen; Jaap Goudsmit; John H McVey; Stuart A Nicklin; Andrew H Baker
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.